公开(公告)号：US20240296960A1

公开(公告)日：2024-09-05

申请号：US18278485

申请日：2022-02-23

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Inventor： BORIS P. KOVATCHEV ,  MARC D. BRETON ,  LEON S. FARHI ,  JAGDISH THAKUR

IPC: G16H50/50 ,  G16H50/70

CPC classification number: G16H50/50 ,  G16H50/70

Abstract: Provided are a method, system and computer-readable storage medium for mapping a metabolic phenotype of a subject to a database entity for creating a digital twin of the subject, and enabling as to such subject, one or more of in silico titration of treatment as to such subject prior to initiating clinical intervention, in silico adjustment and optimization of medication dosing and timing, personalized training through in silico replay of particularized treatment scenario, and tracking over time of any divergence in one or more metabolic traits as between the subject and the digital twin to thereby detect deterioration or improvement in the subject's condition.

公开(公告)号：US20240293047A1

公开(公告)日：2024-09-05

申请号：US18278549

申请日：2022-02-23

Applicant: University of Virginia Patent Foundation

Inventor： BORIS P. KOVATCHEV ,  MARC D. BRETON ,  CHIARA FABRIS ,  DAYU LV

IPC: A61B5/145 ,  A61B5/00 ,  G16H10/20 ,  G16H20/17 ,  G16H50/20 ,  G16H50/50

CPC classification number: A61B5/14532 ,  A61B5/7264 ,  G16H10/20 ,  G16H20/17 ,  G16H50/20 ,  G16H50/50

Abstract: Provided are a method, system and computer-readable storage medium for quantitative physiological assessment and prediction of clinical subtypes of glucose metabolism disorders, including but not limited to, Type 1 diabetes, obesity, pre-diabetes, gestational diabetes, or variants of Type 2 diabetes. The method allows a virtual population of in silico entities to be created, reproducing faithfully the clinical subtype distributions observed in vivo. Potential applications of this method may include, but are not limited to: (a) enabling in silico experiments assessing and/or predicting, for a real patient, treatment or intervention outcomes for a given population/clinical-subtype level; (b) pre-clinical testing of properties of new medications; (c) augmenting limited clinical trial data with in silico experiments to an extent that the domain of their validity and test corner cases may not be observed in vivo.

公开(公告)号：US20220395200A1

公开(公告)日：2022-12-15

申请号：US17776717

申请日：2020-11-16

Applicant: University of Virginia Patent Foundation

Inventor： BORIS P. KOVATCHEV ,  CHIARA FABRIS

IPC: A61B5/145 ,  G16H50/20

Abstract: A method, system, and computer-readable medium for providing a real-time estimation of laboratory glycosylated hemoglobin (HbA1c) at one or more intervals. The real-time estimation is conferred as a value of estimated, time variable A1e (eA1c) based on daily continuous glucose monitoring (CGM)-derived time in target range (TIR) (CGM-TIR). The eA1c value is adjusted based on a sole laboratory HbA1c value for an interval preceding an interval corresponding to the eA1c value so as to provide an expected value for a laboratory HbA1c value at the same corresponding interval.